Benzinga | Nov 3, 2021 09:14AM EDT

HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $55

HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $80 to $55.